Avital Miller

3 weeks ago | healio.com | Jennifer Byrne |Mindy Valcarcel |Avital Miller

Key takeaways: Less than half of phase 3 trials reported toxicity in a guideline-concordant manner. Nearly half of trials used what researchers characterized as toxicity-minimizing language. Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its impact, according to findings published in JCO Oncology Practice.